Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: Relationship with donor age and fibrosis progression

Clinical Transplantation

Volumn 23, Issue 2, 2009, Pages 184-190

  Toniutto, Pierluigi ^a   Minisini, Rosalba ^b   Fabris, Carlo ^a   De Feo, Tullia ^c   Marangoni, Francesca ^c   Burlone, Michela ^b   Avellini, Claudio ^a   Bitetto, Davide ^a   Fornasiere, Ezio ^a   Fumolo, Elisa ^a   Baccarani, Umberto ^a   Pirisi, Mario ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Donor age; Liver fibrosis; Liver transplantation; Occult hepatitis B virus infection; Recurrent hepatitis C

Indexed keywords

ALPHA2B INTERFERON; CORTICOSTEROID; CYCLOSPORIN; HEPATITIS B CORE ANTIBODY; RIBAVIRIN; TACROLIMUS;

ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; ORGAN DONOR; PRIORITY JOURNAL; RECURRENT INFECTION; VIRUS IDENTIFICATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; DISEASE PROGRESSION; DISEASE TRANSMISSION, INFECTIOUS; DNA, VIRAL; FEMALE; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE DONORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 64349104496     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.00964.x     Document Type: Article

References (21)

1. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005: 42: 448.
2. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002: 51: 248.
3. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003: 9: S28.
4. Berenguer M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl 2003: 9: S44.
5. Machicao VI, Bonatti H, Krishna M et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004: 77: 84.
6. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002: 2: 479.
7. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999: 341: 22.
8. Pollicino T, Squadrito G, Cerenzia G et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004: 126: 102.
9. Prieto M, Gomez MD, Berenguer M et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001: 7: 51.
10. Munoz SJ. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002: 8: S82.
11. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective. Liver Transpl 2005: 11: 716.
12. Hui CK, Lau E, Monto A et al. Natural history of patients with recurrent chronic hepatitis C virus and occult hepatitis B co-infection after liver transplantation. Am J Transplant 2006: 6: 1600.
13. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995: 22: 696.
14. Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002: 40: 4068.
15. Frayling IM. Methods of molecular analysis: Mutation detection in solid tumours. Mol Pathol 2002: 55: 73.
16. Pirisi M, Toniutto P, Uzzau A et al. Carriage of HFE mutations and outcome of surgical resection for hepatocellular carcinoma in cirrhotic patients. Cancer 2000: 89: 297.
17. Ghisetti V, Marzano A, Zamboni F et al. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance. Liver Transpl 2004: 10: 356.
18. Hui CK, Lau E, Wu H et al. Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. J Clin Virol 2006: 35: 185.
19. Blanpain C, Knoop C, Delforge ML et al. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: Report on three cases and review of the literature. Transplantation 1998: 66: 883.
20. Neumann UP, Berg T, Bahra M et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004: 41: 830.
21. Toniutto P, Fabris C, Avellini C et al. Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation. World J Gastroenterol 2005: 11: 5944.